<SEC-DOCUMENT>0001193125-25-238989.txt : 20251014
<SEC-HEADER>0001193125-25-238989.hdr.sgml : 20251014
<ACCEPTANCE-DATETIME>20251014160255
ACCESSION NUMBER:		0001193125-25-238989
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20251010
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251014
DATE AS OF CHANGE:		20251014

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FATE THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001434316
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				651311552
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36076
		FILM NUMBER:		251391711

	BUSINESS ADDRESS:	
		STREET 1:		12278 SCRIPPS SUMMIT DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92131
		BUSINESS PHONE:		858.875.1803

	MAIL ADDRESS:	
		STREET 1:		12278 SCRIPPS SUMMIT DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92131
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>fate-20251010.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-10-14T16:00:36.5481+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:fate="http://www.fatetherapeutics.com/20251010" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_de401a22-98e7-4126-97d2-3684345cb728" name="dei:AmendmentFlag" contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d">false</ix:nonNumeric><ix:nonNumeric id="F_40acc67d-dc1c-4217-a62b-409ecbcf86ba" name="dei:EntityCentralIndexKey" contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d">0001434316</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="fate-20251010.xsd"/></ix:references><ix:resources><xbrli:context id="C_8e7c930d-55a0-46a8-959d-34e30a617a0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-10</xbrli:startDate><xbrli:endDate>2025-10-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:2;min-height:1in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3e38bb2c-4e86-4dae-8bb7-983c9aa453da" contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></h2><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_dcb14b54-aecb-4370-8c2d-392f85fef204" contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 10, 2025</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c1e0683-fbd1-4213-b351-8882c8fbe4a9" contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FATE THERAPEUTICS, INC.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:18%;box-sizing:content-box;"/>
     <td style="width:41%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1aa97d92-69d6-40dd-8959-5236a3db2a41" contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5dfb694e-9289-4518-9d27-e6b113087dca" contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-36076</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a7d3011c-cd54-4bb3-ac0e-2f45b8b1a8c2" contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">65-1311552</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission File Number)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c208803e-12f5-47ab-a4ae-a5c40d81eac7" contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12278 Scripps Summit Drive</span></ix:nonNumeric></span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_099f7d07-5069-4221-895d-b25fb9231cd0" contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">San Diego</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_87fecde1-f498-47e9-af6d-088137cb8bff" contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_aab0c2df-6216-4cf4-b347-9195b10d8c7f" contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">92131</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_0a120ee6-27bd-4556-bb3e-adccd91d0c67" contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">858</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_4c3452cc-5ac9-46d5-9ed3-c334b4899035" contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">875-1800</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c294a626-9e1d-4de5-8f3c-60cfe27ae246" contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d" name="dei:EntityInformationFormerLegalOrRegisteredName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">N/A</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:3pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:9.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_83b83042-ec97-40cc-b04e-e83443fa3441" contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:9.5pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:9.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_58d1c89f-d3c2-4ffd-8660-357516571dbf" contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:9.5pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:9.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6753696a-5f7b-4f68-917c-b39c78592901" contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:9.5pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:9.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_30f327b3-4151-4799-9c13-276db7c525a4" contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:9.5pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:45%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Title of each class</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ee9c5dc8-d970-47d9-8062-2cbb414b0c15" contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, $0.001 par value</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_fd410dcd-9f26-422e-84a6-ef6e0ab2804e" contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FATE</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_bd00016e-ed2b-4549-a5b8-caab8a4817ee" contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:9.5pt;"><ix:nonNumeric id="F_984dcfd4-8d30-4d5b-abab-d146209441f7" contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:9.5pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:9.5pt;font-family:Times New Roman;">&#9744;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:1in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 10, 2025, John D. Mendlein, Ph.D., J.D. and Neelufar Mozaffarian, M.D., Ph.D., FACR each provided notice of their respective resignation from the Board, effective as of October 13, 2025.  Dr. Mozaffarian also resigned from her positions on the Board&#8217;s Nominating and Corporate Governance Committee and Science and Technology Committee.  Dr. Mendlein and Dr. Mozaffarian each resigned voluntarily and not as a result of any disagreement with the Company on any matter relating to the Company&#8217;s operations, practices or policies.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the resignations of Drs. Mendlein and Mozaffarian and effective as of October 13, 2025, the Company decreased the size of the Company&#8217;s Board from ten (10) to eight (8) directors (the &#8220;Board Size Decrease&#8221;). The Company effected the Board Size Decrease pursuant to Article VI, Sections 3 and 4 of the Company&#8217;s Amended and Restated Certificate of Incorporation, as amended, and Article II, Section 2 of the Company&#8217;s Amended and Restated Bylaws.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 13, 2025, the Board approved the appointment of Kamal Adawi, M.S., M.B.A., as the Company&#8217;s Chief Financial Officer, such appointment to be effective as of October 20, 2025 (the &#8220;Appointment Date&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to joining the Company, Mr. Adawi, age 46, was the Chief Financial Officer at MiNDERA Corporation (dba Mindera Health) from August 2024 to October 2025. From June 2017 to August 2024, Mr. Adawi was the Chief Financial Officer and Corporate Secretary at Exagen Inc. Prior to serving as Chief Financial Officer at Exagen Inc., Mr. Adawi was the Chief Financial Officer, Corporate Secretary and Treasurer at Pathway Genomics Corporation from 2014 to 2017. Mr. Adawi received a B.A. in Finance from Michigan State University, an M.B.A. from Oakland University, and an M.S. in Finance from San Diego State University.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with Mr. Adawi&#8217;s appointment as the Company&#8217;s Chief Financial Officer, the Company entered into an at-will employment offer letter with Mr. Adawi, dated October 13, 2025 (the &#8220;Offer Letter&#8221;). Pursuant to the Offer Letter, Mr. Adawi is eligible to receive:</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4.259%;box-sizing:content-box;"/>
     <td style="width:3.819%;box-sizing:content-box;"/>
     <td style="width:91.922%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">An annual base salary of $495,000, and is eligible to receive an annual performance bonus with a target bonus amount equal to 40% of his annual base salary;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4.28%;box-sizing:content-box;"/>
     <td style="width:3.86%;box-sizing:content-box;"/>
     <td style="width:91.86%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">An option to purchase 375,000 shares of the Company&#8217;s common stock (the &#8220;Option&#8221;) under the Company&#8217;s Amended and Restated Inducement Equity Plan (the &#8220;Plan&#8221;), with 25% of the shares of common stock underlying the Option vesting on the first anniversary of the Appointment Date, and the balance vesting in equal monthly installments over the next 36 months, subject to Mr. Adawi&#8217;s continued service to the Company through each vesting date and subject to acceleration under certain circumstances as set forth in the Severance Policy (as defined below);</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4.3%;box-sizing:content-box;"/>
     <td style="width:3.84%;box-sizing:content-box;"/>
     <td style="width:91.86%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">An award of restricted stock units for 75,000 shares of the Company&#8217;s common stock (the &#8220;RSUs&#8221;) under the Plan, with 25% of the shares of common stock underlying the RSUs vesting in equal annual installments over four years from November 1, 2025, subject to Mr. Adawi&#8217;s continued service to the Company through each vesting date; and</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4.28%;box-sizing:content-box;"/>
     <td style="width:3.82%;box-sizing:content-box;"/>
     <td style="width:91.9%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Benefits under the Company&#8217;s Severance and Change in Control Policy (the &#8220;Severance Policy&#8221;), employee health benefits program, 401(k) plan, bonus plan and vacation plan, subject to the terms of those plans.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing summary of the Offer Letter does not purport to be complete and is qualified in its entirety by reference to the complete Offer Letter, which is filed as Exhibit 10.1 with this Current Report on Form 8-K and is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as described above, there are no understandings or arrangements between Mr. Adawi and any other person pursuant to which he was appointed as Chief Financial Officer of the Company, and Mr. Adawi has no material interest</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:1in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in any transaction or proposed transaction in which the Company is or is to be a party. Mr. Adawi has no family relationship with any director or executive officer of the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 13, 2025, the Board also approved the appointment of Mr. Adawi as the Company&#8217;s principal financial officer and principal accounting officer, replacing Bahram Valamehr in these positions, effective as of the Appointment Date. Dr. Valamehr will continue to serve as a Director and the Company&#8217;s President and Chief Executive Officer, and principal executive officer.</span></p><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7.01 Regulation FD Disclosure.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 14, 2025, the Company issued a press release announcing Mr. Adawi&#8217;s appointment as Chief Financial Officer of the Company. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></h2><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(d) Exhibits.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:11%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:88%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit No.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="height:6.75pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="fate-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Offer Letter between the Company and Kamal Adawi, dated as of October 13, 2025</span></a></p></td>
    </tr>
    <tr style="height:6.75pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="fate-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release issued by Fate Therapeutics, Inc. on October 14, 2025, furnished herewith</span></a></p></td>
    </tr>
    <tr style="height:6.75pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:1in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:44%;box-sizing:content-box;"/>
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:46%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">FATE THERAPEUTICS, INC.</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 14, 2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Bahram Valamehr</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bahram Valamehr, Ph.D., M.B.A.<br/>President and Chief Executive Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>fate-ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2025-10-14T16:00:36.5333+00:00 --><!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">October 13, 2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Kamal Adawi</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Dear Kamal:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">	Fate Therapeutics, Inc. (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Fate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; or the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;) is pleased to offer you an exempt full-time position as Chief Financial Officer, reporting to the Company&#x2019;s President &amp; Chief Executive Officer.  This position has an anticipated start date of October 20, 2025 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Start Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;), and requires that you provide full-time services at the Company&#x2019;s corporate headquarters in San Diego, California during the Company&#x2019;s business days of operation.  Additional information is outlined below.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Compensation &amp; Benefits</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">As an exempt employee, you will be paid an initial annualized base salary of $495,000. This salary will be paid, less applicable state and federal taxes and withholdings, in accordance with our standard payroll practices, which currently is every two weeks.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">You will also be eligible to participate in our employee benefits program, which includes health benefits, paid time off, and a 401(k) plan. You will also be designated as an &#x201c;Eligible Employee&#x201d; under the Company&#x2019;s Severance and Change in Control Policy, as amended from time to time (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Severance Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;), and will be eligible for benefits under the Severance Policy subject to and in accordance with the terms of the Severance Policy. A detailed overview of our benefits will be sent to you under separate cover.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Bonus Plan</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The Company has determined your annual target bonus will be 40.0% of your then-existing annual base salary, and that target will be prorated for your initial calendar year of employment; provided, however that in any event the award and actual amount of any bonus (including any shares of Company common stock payable) will be determined, and payment thereof made, in accordance with the terms and conditions of the Company&#x2019;s Amended and Restated Senior Executive Incentive Bonus Plan, as amended from time to time (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Incentive Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;), and any such bonus will be subject to the discretion and approval of the Company&#x2019;s Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;) or the Compensation Committee thereof (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Compensation Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;). In the event that you are awarded an annual bonus, such bonus shall be paid at the time and in the manner in which annual bonuses are paid to other executive officers of the Company also awarded an annual bonus. Under the Incentive Plan, bonus payouts are subject to the Company achieving its performance targets and may be adjusted based upon you meeting your individual performance objectives, as determined by the Board or Compensation Committee, as applicable, in its sole discretion. Payments arising out of the Incentive Plan are discretionary and not designed to be part of your regular compensation. You must be actively employed by the Company on the date the bonus is paid to have earned and be eligible for the bonus. We reserve the right to amend the Incentive Plan at any time.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Equity Award</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Subject to approval by our Board or the Compensation Committee, you will be granted:</font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">an award of 75,000 restricted stock units (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Award</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;) with each restricted stock unit equal to one share of the Company&#x2019;s common stock. The &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Vesting Base Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; of the Award will be November 1, 2025. The Award will vest in accordance with the following schedule: twenty-five percent (25%) of the restricted stock units underlying the Award will vest on each anniversary of the Vesting Base Date, so that one hundred percent (100%) of the restricted stock units underlying the Award will be vested on </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">the fourth (4</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">) anniversary of the Vesting Base Date, in each case subject to your continued service relationship with the Company through the applicable vesting date.</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">a nonqualified stock option award to purchase 375,000 shares of the Company&#x2019;s common stock at an exercise price per share equal to the closing price per share of the Company&#x2019;s common stock as reported on NASDAQ on the date of grant (the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;Option&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">). The Option will vest and become exercisable in accordance with the following schedule: twenty-five percent (25%) of the shares subject to the Option will vest and become exercisable on the first anniversary of your Start Date; thereafter, 1/36</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> of the remaining shares subject to the Option will vest and become exercisable on a monthly basis so that one hundred percent (100%) of the shares subject to the Option will be vested and exercisable on the date four years after your Start Date, in each case subject to your continued service relationship with the Company through the applicable vesting date. </font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The Option and the Award will be subject to the terms and conditions of the Company&#x2019;s Inducement Equity Plan (as amended, restated or otherwise modified from time to time, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Inducement Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;). Your eligibility to receive the Option and the Award is subject to your executing certain award-related documentation pursuant to the Inducement Plan. You will receive additional grant information from the Company&#x2019;s equity plan administrator separately. Fate reserves the right to amend its equity plan(s) at any time.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">No Conflicts and Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">	By accepting this offer, you confirm that (i) you have no contractual commitments or other legal obligations that would prohibit you from performing your job duties for the Company (including non-competition clauses) and (ii) you will not, at any time during your employment with Fate, breach any obligation or agreement that you have entered into with any third party, including your former employers. In addition, following your Start Date and throughout your employment with Fate, you agree that you will not engage in any other employment, consulting, or other business activity (whether full-time or part-time) unless approved in writing by the Company&#x2019;s Chief Executive Officer or Chief Legal Officer.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">	You also agree that, in the course of your employment with us, you will not use or disclose any confidential information or trade secrets, if any, of any former employer or other person to whom you have an obligation of confidentiality. Rather, you will be expected to use in the performance of your duties only that information which is generally known and used by persons with training and experience comparable to your own, which is common knowledge in the industry or otherwise legally in the public domain, or which otherwise is provided or developed by us. You further agree that you will not bring onto our premises, or transfer to any of our computers, servers, or systems, any confidential or proprietary document or property belonging to any former employer or other person to whom you have an obligation of confidentiality. A full summary of our expectations is set out in the PIIA (discussed below).</font></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Company Policies and Procedures</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">As a condition of employment, you must review, accept, and comply with all of Fate&#x2019;s policies and procedures, including, without limitation, our Code of Business Conduct and Ethics, our Insider Trading Policy, and our Employee Handbook. We may adopt additional policies or procedures in the future, and you may be required to sign certain documents acknowledging your receipt and understanding of these and other documents. Violation of any of our policies or procedures would be cause for disciplinary action, up to and including termination of employment.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">At-Will Employment</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Although Fate anticipates a mutually rewarding employment relationship, it is expressly understood and agreed that your employment is &#x201c;at will.&#x201d; Under this relationship, you are not guaranteed employment for any</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">specific period and both you and Fate have the right to terminate your employment at any time, with or without cause or prior notice. You further acknowledge that nothing in this offer letter, its attachments, or our policies or procedures shall affect or change your employment-at-will status.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Eligibility Verification</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Under federal employment and immigration laws, the Company is required to verify each new employee's identity and legal authority to work in the United States. Accordingly, please be prepared to furnish appropriate documents satisfying those requirements as this offer of employment is conditioned on submission of satisfactory documentation and its verification.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Offer Letter Agreement</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">	Please note that it is a condition of employment that you review, accept and sign Fate&#x2019;s Proprietary Information and Inventions Agreement, a copy of which is attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Attachment 1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">PIIA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;), and Fate&#x2019;s Mutual Dispute Resolution Agreement, a copy of which is attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Attachment 2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">DRA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">This offer letter, together with the PIIA and DRA, will govern the terms and conditions of your employment at Fate, and the offer letter shall be governed by and construed in accordance with laws of the state in which you reside, as applied to agreements entered into and to be fully performed by residents of such state. This offer letter supersedes and replaces all prior understandings, communications and agreements regarding the same. The terms and conditions of this offer letter may be changed only by written agreement by a duly authorized representative of Fate, although Fate may, from time to time, in its sole discretion, adjust the salary, benefits, other forms of compensation paid to you, and/or other policies and procedures in connection with your employment. Fate&#x2019;s offer of employment is also contingent upon the satisfactory completion of Fate&#x2019;s pre-employment screening process, including a background check and references.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Please sign (either by hand or electronically) and return a copy of this offer letter, as well as the PIIA and the DRA, by October 13 to confirm your acceptance of these terms, it being understood that this offer will expire if not accepted on or before such date (although that expiration date may be extended at the discretion of Fate).  Your signature on this Offer Letter certifies that you agree with all terms stated herein.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">If you have any questions regarding this offer, please let us know and we will be happy to discuss.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Kamal, we are excited to have you join Fate!</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Sincerely,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">                                          </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">             </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">/s/ Bob Valamehr</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Bob Valamehr			</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">President &amp; CEO				</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Acceptance of Agreement by Employee</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">I, Kamal Adawi, confirm that I have had a reasonable opportunity to review and consider the terms, conditions and representations made in this offer letter, as well as to obtain independent legal advice regarding the offer. By my signature below, I accept this offer for employment at Fate.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:33.333%;box-sizing:content-box;"></td>
     <td style="width:33.333%;box-sizing:content-box;"></td>
     <td style="width:33.333%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Signature:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;/s/ Kamal Adawi</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">10/13/2025</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:36pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.667%;text-indent:0;font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Kamal Adawi</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Date</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Appendix A</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Employee Proprietary Information and Inventions Agreement</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Appendix B</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Mutual Dispute Resolution Agreement</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>fate-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2025-10-14T16:00:36.5471+00:00 --><!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img158830969_0.jpg" alt="img158830969_0.jpg" style="width:140px;height:77px;"></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">San Diego, CA &#x2013; October 14, 2025</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> &#x2013; Fate Therapeutics, Inc. (NASDAQ: FATE) (the Company), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Kamal Adawi, M.S., M.B.A., to the role of Chief Financial Officer (CFO) effective October 20, 2025. Mr. Adawi brings to the Company more than 20 years of financial leadership experience in the life sciences industry, including over 10 years serving as CFO across innovative life science companies, with deep domain expertise in autoimmune diseases, including lupus.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;We are excited to welcome Kamal, a seasoned life sciences executive with extensive experience leading autoimmune-focused companies, at this pivotal moment in our company&#x2019;s evolution,&#x201d; said Bob Valamehr, Ph.D., M.B.A., President and Chief Executive Officer of Fate Therapeutics. &#x201c;Having served as CFO of multiple life science companies in various stages of growth, Kamal brings proven expertise in financial strategy, capital formation, and operational growth. As our clinical programs continue to meaningfully progress, including the development of the registrational path for FT819 in SLE, his leadership will be instrumental in supporting our strategy to transform the treatment landscape for autoimmune diseases and cancer.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Mr. Adawi was most recently the CFO of Mindera Health, a precision medicine company helping physicians optimize treatment for autoimmune skin disorders. Prior to Mindera Health, Mr. Adawi served for over seven years as the CFO and Corporate Secretary of Exagen Inc., a leader in rheumatology testing with a flagship product in lupus diagnostics. During his tenure, he led Exagen through a successful IPO and oversaw its transition to a public entity while continuing to scale the company. Mr. Adawi also held the CFO role at Pathway Genomics, as well as other financial leadership positions at Becton Dickinson, GenMark Dx and Digirad Corporation, contributing to capital strategy, financial operations, and long-term growth initiatives. Mr. Adawi holds a B.A. in Finance from Michigan State University, an M.B.A. from Oakland University, and an M.S. in Finance from San Diego State University.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;I am thrilled to join Fate Therapeutics at such an exciting time, as the Company paves the path for its registrational trial of FT819 in SLE,&#x201d; said Mr. Adawi. &#x201c;Fate&#x2019;s approach to developing off-the-shelf cellular immunotherapies, designed to be broadly accessible with less intensive or no conditioning chemotherapy, is highly differentiated and has the potential to meaningfully shift the current treatment paradigm for patients living with autoimmune diseases and cancer. I am honored to work alongside the talented and dedicated team at Fate to bring forward a pipeline of innovative and potentially game-changing therapies.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">In connection with his commencement of employment, the Company will grant Mr. Adawi an option to purchase 375,000 shares of the Company&#x2019;s common stock with an exercise price equal to the closing price per</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">share of the Company&#x2019;s common stock as reported by NASDAQ on October 20, 2025, which will be the date of commencement of Mr. Adawi&#x2019;s employment with the Company and the effective date of grant. The option is a non-qualified stock option and vests over a period of four years, with twenty-five percent vesting on the one-year anniversary of the grant date and the remaining seventy-five percent vesting in approximately equal monthly increments over the succeeding thirty-six months, subject to Mr. Adawi&#x2019;s continuous employment through each vesting date and subject to acceleration under certain circumstances as set forth in the Company&#x2019;s Severance and Change in Control Policy. In addition, the Company will grant Mr. Adawi an award of 75,000 restricted stock units, with each restricted stock unit equal to one share of the Company&#x2019;s common stock. Twenty-five percent (25%) of the restricted stock units vest on November 1, 2026, and thereafter twenty-five percent (25%) of the restricted stock units shall vest on each anniversary of such vesting date, subject to Mr. Adawi&#x2019;s continuous employment through each vesting date. The option and the restricted stock unit award each will be granted as an inducement material to Mr. Adawi entering into employment with Fate Therapeutics in accordance with Nasdaq Listing Rule 5635(c)(4), and will be granted pursuant to the Company&#x2019;s Amended and Restated Inducement Equity Plan.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">About Fate Therapeutics, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company&#x2019;s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">This release contains &#x201c;forward-looking statements&#x201d; within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the advancement of, plans related to, and the therapeutic potential of the Company&#x2019;s product candidates, the Company&#x2019;s clinical development and manufacturing strategies, and the Company&#x2019;s plans for the clinical investigation and manufacture of its product candidates. These and any other forward-looking statements in this release are based on management&#x2019;s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company&#x2019;s research and development programs and product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company&#x2019;s product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the manufacturing of the Company&#x2019;s product candidates or in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Company&#x2019;s product candidates are being developed, the amount and type of data to be generated, or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company&#x2019;s ongoing and planned clinical trials, difficulties in manufacturing or supplying the Company&#x2019;s product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), and the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company&#x2019;s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company&#x2019;s periodic filings with the Securities and Exchange Commission, including but not limited to the Company&#x2019;s most recently filed periodic report, and from time to time in the Company&#x2019;s press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Contact:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Christina Tartaglia</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Precision AQ</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">212.362.1200</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">christina.tartaglia@precisionaq.com</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img158830969_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img158830969_0.jpg
M_]C_X  02D9)1@ ! 0        #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "P 4 # 2(  A$! Q$!_\0
M'P   @(" P$! 0            D("@<+ 0,&!00"_\0 <A   0,# P$#! 40
M$@@1#0  ! $%!@(#!P ($2$)%#$2$Q5!%B116&$*%Q@9(B,V.'%V>(&1E[76
M)28R-#4W5W5WE9:AL;2VM]37&C-25'*8P=$G.4)%1E-98F5S=)3"X>3P\2A#
M1TA68V1H>8>RL\?_Q  = 0$  @(# 0$              @,'"0$$" 4&_\0
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MX>L5N;./I!HT:-617!HTX[&78A[K\KXVQWE.-SW;^''\F06)9 80WN59#'>
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M?ZA@3NYGWB@?\KAWT>]ARI^TMK^EZ/E<.^CWL.5/VEM?TO5_#1IUG=S_ %#
MG=S/O%#['O9S;WAY["B3MM63&\(:6QR\:>2T6;8X8EAX!OWS"/;7084?VRJ_
M:U?!T:-14HJI79O-8E'CY_\ 0)-/K5DGX(.UK9];)G(*\02:+[D3D?X&-Y_>
MUK9M2;V\/6*W-G'T@T:-&K(KC87[+?I.]IOV-6"/YJXKJ3.HS;+?I.]IOV-6
M"/YJXKJ3.NO'8@T:-&D(_CE*DY5.*?%%1>?@]S7GY(Q@2=D=&1T$'.;70 H
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MB#KC:IH TMR%^;N2]ESLPA%XK,8:EYMIQ24N3*$!*$OM G[DK2!B"<TJ!%*
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MZZ75LWRO59=@.V&S+IG7%4=2ZHJ0$ *H1E4G56FW;G&.](_1>E;DW0M6\ O
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MP_7P%$$[GX^[KJ^6'[X_?39E_=>;J&FOH,[0[2%W:X_'VMP?'Q\<@&=D9&<
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M:-89W!3UXQ5@C->4(_8;S'[&^)<CSYG"=[-\AH-<X=#WB0@!NM@8D(J\WDE
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JZ66,ZQ-9A(X_W1$($=VEC=>ZNBLQ81L-C;)\;\)/9(\R-TFC1KB$?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>fate-20251010.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-10-14T16:00:36.8134+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.fatetherapeutics.com/20251010" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:fate="http://www.fatetherapeutics.com/20251010" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="fate-20251010.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Information, Former Legal or Registered Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName" order="10150.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 10, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 10,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">FATE THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001434316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-1311552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12278 Scripps Summit Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">875-1800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FATE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="fate-20251010.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="fate-20251010.htm">fate-20251010.htm</File>
    <File>fate-20251010.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "fate-20251010.htm": {
   "nsprefix": "fate",
   "nsuri": "http://www.fatetherapeutics.com/20251010",
   "dts": {
    "inline": {
     "local": [
      "fate-20251010.htm"
     ]
    },
    "schema": {
     "local": [
      "fate-20251010.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_8e7c930d-55a0-46a8-959d-34e30a617a0d",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20251010.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e7c930d-55a0-46a8-959d-34e30a617a0d",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20251010.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.fatetherapeutics.com/20251010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001193125-25-238989-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-238989-xbrl.zip
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ME-^G#8G #6RTD;=ZY$3>F"3I.  8#9F']-^VAO>' Q;?B+#-1FGT/V(PC&(
M?GKX7U@&C]^WE4-ZQYUO(J78+DW$?SEEWG]&2=I6%>7GPV&4")Q+.^8!0Z9Q
MN"='ZXG;HC-/),. C1%S\.N1N&_CF'B<_12>QT/Y<XI:1'@?]L[^[7%#41G
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MB<M&V3'Q F-%2ND]^2T"49;+X_ ^"WS4Y;&A+!4C*X!*^@C/!)7- 9OI1S$
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MO,7GP6>'LE< #I_A-;L0%8Y"2@H:T#9\^_GE$EJ%Q:*+HLFR#2GZ6_"([6@
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M<3%5>72MA*\L&]WXLQ&BA2Q3(;52&V"#4#:O#^8H0>I=$)^U[:*T;Y67JEE
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MP6=:X71HE0" ^*-6-#.,D_0S^/0.#I^K;-:M&8(6$#&,TV/P3-84C^'YC35
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M";XRRF]".%U3K1L3_[*N93HG*,=)KIN1&Y]TE#!$2A%JRI>,K&QB( 'D(/;
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M?W?RD/\EMO\#4$L! A0#%     @ 6H!.6U<FK<CD&P  WOP  !$
M     ( !     &9A=&4M,C R-3$P,3 N:'1M4$L! A0#%     @ 6H!.6[EJ
MJ+ZJ"   \&$  !$              ( !$QP  &9A=&4M,C R-3$P,3 N>'-D
M4$L! A0#%     @ 6H!.6\)N$]PK%@  4JL   \              ( !["0
M &9A=&4M97@Q,%\Q+FAT;5!+ 0(4 Q0    ( %J 3EM1@P7HXA   &Q.   /
M              "  40[  !F871E+65X.3E?,2YH=&U02P4&      0 ! #X
)    4TP

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>fate-20251010_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="fate-20251010.xsd" xlink:type="simple"/>
    <context id="C_8e7c930d-55a0-46a8-959d-34e30a617a0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
        </entity>
        <period>
            <startDate>2025-10-10</startDate>
            <endDate>2025-10-10</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d"
      id="F_de401a22-98e7-4126-97d2-3684345cb728">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d"
      id="F_40acc67d-dc1c-4217-a62b-409ecbcf86ba">0001434316</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d"
      id="F_3e38bb2c-4e86-4dae-8bb7-983c9aa453da">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d"
      id="F_dcb14b54-aecb-4370-8c2d-392f85fef204">2025-10-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d"
      id="F_4c1e0683-fbd1-4213-b351-8882c8fbe4a9">FATE THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d"
      id="F_1aa97d92-69d6-40dd-8959-5236a3db2a41">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d"
      id="F_5dfb694e-9289-4518-9d27-e6b113087dca">001-36076</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d"
      id="F_a7d3011c-cd54-4bb3-ac0e-2f45b8b1a8c2">65-1311552</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d"
      id="F_c208803e-12f5-47ab-a4ae-a5c40d81eac7">12278 Scripps Summit Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d"
      id="F_099f7d07-5069-4221-895d-b25fb9231cd0">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d"
      id="F_87fecde1-f498-47e9-af6d-088137cb8bff">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d"
      id="F_aab0c2df-6216-4cf4-b347-9195b10d8c7f">92131</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d"
      id="F_0a120ee6-27bd-4556-bb3e-adccd91d0c67">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d"
      id="F_4c3452cc-5ac9-46d5-9ed3-c334b4899035">875-1800</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName
      contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d"
      id="F_c294a626-9e1d-4de5-8f3c-60cfe27ae246">N/A</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:WrittenCommunications
      contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d"
      id="F_83b83042-ec97-40cc-b04e-e83443fa3441">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d"
      id="F_58d1c89f-d3c2-4ffd-8660-357516571dbf">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d"
      id="F_6753696a-5f7b-4f68-917c-b39c78592901">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d"
      id="F_30f327b3-4151-4799-9c13-276db7c525a4">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d"
      id="F_ee9c5dc8-d970-47d9-8062-2cbb414b0c15">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d"
      id="F_fd410dcd-9f26-422e-84a6-ef6e0ab2804e">FATE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d"
      id="F_bd00016e-ed2b-4549-a5b8-caab8a4817ee">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_8e7c930d-55a0-46a8-959d-34e30a617a0d"
      id="F_984dcfd4-8d30-4d5b-abab-d146209441f7">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
